Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
JAZZ 
Jazz Pharmaceuticals PLC (JAZZ)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/03/2025: JAZZ (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
18 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $208.5
1 Year Target Price $208.5
| 10 | Strong Buy |
| 6 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 22.81% | Avg. Invested days 46 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/03/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 10.15B USD | Price to earnings Ratio - | 1Y Target Price 208.5 |
Price to earnings Ratio - | 1Y Target Price 208.5 | ||
Volume (30-day avg) 18 | Beta 0.33 | 52 Weeks Range 95.49 - 182.99 | Updated Date 12/3/2025 |
52 Weeks Range 95.49 - 182.99 | Updated Date 12/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.17 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-05 | When - | Estimate 5.96 | Actual 8.13 |
Profitability
Profit Margin -8.86% | Operating Margin (TTM) 22.33% |
Management Effectiveness
Return on Assets (TTM) 4.88% | Return on Equity (TTM) -9.06% |
Valuation
Trailing PE - | Forward PE 8.23 | Enterprise Value 13512607488 | Price to Sales(TTM) 2.44 |
Enterprise Value 13512607488 | Price to Sales(TTM) 2.44 | ||
Enterprise Value to Revenue 3.25 | Enterprise Value to EBITDA 73.7 | Shares Outstanding 60765116 | Shares Floating 58857699 |
Shares Outstanding 60765116 | Shares Floating 58857699 | ||
Percent Insiders 3 | Percent Institutions 103.77 |
Upturn AI SWOT
Jazz Pharmaceuticals PLC
Company Overview
History and Background
Jazz Pharmaceuticals PLC was founded in 2003. Initially focused on sleep disorders, it has grown through acquisitions and internal development, expanding its product portfolio to include treatments for oncology and epilepsy.
Core Business Areas
- Sleep: Focuses on treatments for sleep disorders, including excessive daytime sleepiness in narcolepsy.
- Oncology: Develops and commercializes therapies for various types of cancer.
- Epilepsy: Develops and commercializes therapies for the treatment of seizures associated with epilepsy.
Leadership and Structure
Bruce Cozadd serves as the Chairman and CEO. The organizational structure includes various departments focused on research and development, commercial operations, and corporate functions.
Top Products and Market Share
Key Offerings
- Xyrem/Xywav: Indicated for narcolepsy with cataplexy or excessive daytime sleepiness. Xywav is a lower-sodium formulation of Xyrem. Faces competition from generics and other stimulants. Xyrem/Xywav revenues were approximately $1.97 billion in 2023.
- Epidiolex/Epidyolex: A cannabidiol (CBD) oral solution approved for seizures associated with several rare forms of epilepsy. Competitors include other anti-epileptic drugs. Epidiolex/Epidyolex revenues were approximately $736 million in 2023.
- Rylaze: A recombinant Erwinia asparaginase indicated as a component of a multi-agent chemotherapeutic regimen for acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in pediatric and adult patients who have developed hypersensitivity to native forms of L-asparaginase. Main competitors would be other L-asparaginase products. Rylaze revenue was $403 million in 2023.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, strict regulatory oversight, and intense competition. It is experiencing growth driven by aging populations and advancements in biotechnology.
Positioning
Jazz Pharmaceuticals holds a strong position in the sleep disorder and epilepsy markets, particularly with its Xyrem/Xywav and Epidiolex/Epidyolex products. It has a competitive advantage through its established market presence and specialized product portfolio.
Total Addressable Market (TAM)
The global market for sleep disorder therapeutics is expected to reach $12.3 billion by 2028. The global epilepsy therapeutics market is projected to reach $13.9 billion by 2029. Jazz Pharmaceuticals is positioned to capture a significant share through its established products and ongoing development efforts.
Upturn SWOT Analysis
Strengths
- Strong market position in sleep disorder treatments
- Diversified product portfolio
- Established distribution network
- Experienced management team
- Acquisition Expertise
Weaknesses
- Reliance on key products
- Exposure to generic competition
- High debt levels (related to acquisitions)
- Regulatory risks
Opportunities
- Expansion into new therapeutic areas
- Strategic acquisitions
- International market expansion
- Advancements in drug delivery technologies
Threats
- Increasing generic competition
- Changes in healthcare regulations
- Pricing pressures
- Clinical trial failures
Competitors and Market Share
Key Competitors
- TEVA
- VRX
- LUPIN
Competitive Landscape
Jazz Pharmaceuticals competes primarily based on product efficacy, safety, and market access. Its competitive advantages include its established market position and specialized product portfolio. Disadvantages include reliance on key products and exposure to generic competition.
Major Acquisitions
Cavion Biosciences
- Year: 2019
- Acquisition Price (USD millions): 312.5
- Strategic Rationale: Expanded neuroscience pipeline with focus on essential tremor and other neurological disorders.
GW Pharmaceuticals
- Year: 2021
- Acquisition Price (USD millions): 7200
- Strategic Rationale: Diversifies product portfolio with Epidiolex/Epidyolex and strengthens position in cannabinoid-based therapies.
Growth Trajectory and Initiatives
Historical Growth: Jazz Pharmaceuticals has experienced steady growth through product launches, acquisitions, and market expansion.
Future Projections: Analysts project continued revenue growth driven by key products and potential pipeline developments.
Recent Initiatives: Recent initiatives include strategic acquisitions to expand its product portfolio and investment in R&D to develop new therapies.
Summary
Jazz Pharmaceuticals is a strong company with a diversified portfolio and solid market positions, especially in sleep disorders and epilepsy. The acquisition of GW Pharmaceuticals was a strategic move, but the company has substantial debt from acquisitions. It needs to manage generic competition and pricing pressures while continuing to innovate to improve future growth and mitigate risk.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Filings (10-K, 10-Q)
- Investor Presentations
- Analyst Reports
- Company Website
- SEC Filings
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a financial professional. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Jazz Pharmaceuticals PLC
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2007-06-01 | President, CEO & Director Ms. Renee D. Gala | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2800 | Website https://www.jazzpharma.com |
Full time employees 2800 | Website https://www.jazzpharma.com | ||
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Defitelio to treat severe veno-occlusive disease; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab in Phase 3 trial to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Epidiolex in Phase 3 trial to treat LGS, DS, and TSC; Suvecaltamide in Phase 2 trial to treat Parkinson's disease tremor; JZP815, a pan-RAF kinase inhibitor in Phase 1 trial that targets components of the mitogen-activated protein kinase; JZP898, a conditionally activated interferon alpha molecule in Phase 1 trial; JZP441 in Phase 1 trial to treat narcolepsy, IH, and other sleep disorders; JZP324, an extended-release low sodium oxybate formulation in Phase 1 trial for patients with sleep disorders; and JZP150 to treat post-traumatic stress disorder. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.